National Bone Health Alliance Bone Turnover Marker Project: Current practices and the need for US harmonization, standardization, and common reference ranges

Osteoporosis International

Volumn 23, Issue 10, 2012, Pages 2425-2433

  Bauer, D ^a   Krege, J ^b   Lane, N ^c   Leary, E ^d   Libanati, C ^e   Miller, P ^f   Myers, G ^g   Silverman, S ^h   Vesper, H W ⁱ   Lee, D ^j   Payette, M ^k   Randall, S ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Pacific Biomarkers   (United States)

^e AMGEN INC   (United States)

^f University of Colorado Health Sciences Center   (United States)

^g American Association for Clinical Chemistry ^*  (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j National Bone Health Alliance   (United States)

^k Roche Diagnostics Corporation   (United States)

^l Interspecialty Medical Council   (United States)

more..

Author keywords

Bone turnover markers; Position paper

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANABOLIC AGENT; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; EDETIC ACID;

ACCURACY; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL CHEMISTRY; CLINICAL DECISION MAKING; CLINICAL LABORATORY; CLINICAL PRACTICE; COLLAGEN SYNTHESIS; COST EFFECTIVENESS ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FOOD AND DRUG ADMINISTRATION; FRACTURE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; ORGANIZATION; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY CONTROL; RADIOIMMUNOASSAY; REFERENCE VALUE; RISK; SERUM; STANDARDIZATION; TREATMENT RESPONSE; UNITED STATES;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; COLLAGEN TYPE I; HUMANS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PROFESSIONAL PRACTICE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 84867335094     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2049-z     Document Type: Article

References (53)

1. NOF (2010) NOF clinician's guide to prevention and treatment of osteoporosis. NOF, Washington
2. Schafer AL L, Vittinghoff E, Ramachandran R, Mahmoud N, Bauer DC (2010) Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 21:439-455
3. Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int 22(2):391-420
4. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of Cterminal telopeptide of type 1 collagen (serum s-CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting. Bone 31:57-61
5. Clowes JA, Hannon RA, Yap TA, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886-890
6. Rifai N, Cooper GR, Brown WV, Friedewald W, Havel RJ, Myers GL, Warnick GR (2004) Clinical chemistry journal has contributed to progress in lipid and lipoprotein testing for fifty years. Clin Chem 50:1861-1870
7. Little RR, Rohlfing CL, Sacks DB, National Glycohemoglobin Standardization Program (NGSP) Steering Committee (2011) Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 57:205-214
8. Miller WG, Myers GL, Rej R (2006) Why commutability matters. Clin Chem 52:553-554
9. Miller WG, Myers GL, Gantzer LM, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, Nübling CM, Sturgeon CM (2011) Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 57:1108-1117
10. Clinical and Laboratory Standards Institute (CLSI). www. CLSI.org. Accessed 16 Jan 2012
11. Serum CrossLaps®ELISA, Immunodiagnostic systems, Inc. technical manual. http://www.idsplc.com. Accessed 16 Jan 2012
12. CrossLaps/Serum, Roche Diagnostics. Technical manual. http://www.roche.com. Accessed 16 Jan 2012
13. intact PINP, Immunodiagnostic Systems, Inc. technical manual. http://www.idsplc.com. Accessed 16 Jan 2012
14. total PINP, Roche Diagnostics technical manual. http://www.roche.com. Accessed 16 Jan 2012
15. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623-630
16. Glover S, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley J, Black D, Delmas P, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 24:389-397
17. de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222-1230
18. Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, Dimunno O, Frediani B, Rossini M (2008) Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 82:341-347
19. Cavalier E, Delanaye P (2009) Letter to the editor: Defining a "reference population": no easy task. JBMR 24:1638
20. Eastell R, Glover SJ, Gall M, Schoenborn-Kellenberger O, Garnero P, Black D (2009) Defining a "reference population": no easy task. JBMR 24:1639
21. Linnet K (1987) Two-stage transformation systems for normalization of reference distributions evaluated. Vlin Vhrm 33:381-386
22. Baim S, Miller PD (2009) Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561-573
23. Keaveny TM, Kopperdahl DL, Melton LJ III, Hoffman PF, Amin S, Riggs BL, Khosla S (2010) Age-dependence of femoral neck strength in white women and men. J Bone Miner Res 25(5):994-1001
24. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung MR, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Markers Standard Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391-420
25. Melton LJ III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083-1091
26. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526-1536
27. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813-1819
28. Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporosis Int 11(Suppl 6):S55-S65
29. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538
30. Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ (2010) Bone turnover markers and prediction of fracture: a prospective follow-up study of 1, 040 elderly women for a mean of 9 years. J Bone Miner Res 25:393-403
31. Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E (2009) Osteoporotic fractures in men (MrOs) Research Group. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOs Study. J Bone Miner Res 24(12):2032-2038
32. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100-103
33. Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:89-93
34. Papapolpous S, Schimmer RC (2007) Changes in bone remodeling and anti-fracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66(7):853-858
35. Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
36. Christiansen C, Riis BJ, Rodbro P (1987) Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105-1108
37. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P (2007) Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18:1297-1305
38. Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398-1404
39. Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with longterm changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762-2767
40. Hannon RA, Bluhmson A, Naylor KE, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy. J Bone Miner Res 13:1124-1133
41. Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS (2005) Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667-674
42. Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237-244
43. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363-2368
44. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431-1438
45. Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85:3537-3540
46. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
47. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronatetreated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258
48. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351
49. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832-836
50. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798-803
51. Porter D, Pienowski D, Monier-Faugere MC, Mallluche H (2012) Difference in bone quality between high versus low turnover renal osteodystrophy. JASN (in press)
52. Nickolas T, Cremers S, Zhang A, Stein E, Cohen A, Chauncey R, Nikkel L, Liu X, Boutroy S, Yin M, Staron R, Leonard M, McMahon D, Dworakowski E, and Shane E (2012) Biochemical markers of bone turnover discriminate fracture status in patients with pre-dialysis chronic kidney disease. JASN (in press)
53. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475